PCSK9 inhibitors conquer primary prevention: the VESALIUS-CV study

Area of Science:

• Cardiology
• Pharmacology
• Preventive Medicine

Background:

• Elevated low-density lipoprotein cholesterol (LDL-C) is a primary driver of atherosclerotic cardiovascular disease.
• Many high-risk patients do not achieve target LDL-C levels with statin therapy alone, necessitating additional treatments.
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, like evolocumab, effectively reduce LDL-C and cardiovascular risk.

Purpose of the Study:

• To evaluate the efficacy and safety of evolocumab in primary prevention for high cardiovascular risk patients.
• To assess the role of evolocumab in reducing major adverse cardiovascular events in a broad patient population.

Main Methods:

• The VESALIUS-CV trial investigated evolocumab's impact on LDL-C reduction and cardiovascular outcomes.
• A placebo-controlled study design was employed to assess the safety and efficacy profile.
• Participants included high cardiovascular risk individuals without prior major cardiovascular events.

Main Results:

• Evolocumab demonstrated significant and sustained LDL-C reduction (approximately 60%).
• The trial showed a significant reduction in the risk of first cardiovascular events, including myocardial infarction and revascularization.
• Evolocumab exhibited a safety profile comparable to placebo.

Conclusions:

• Evolocumab is an effective and safe strategy for cardiovascular risk reduction in both primary and secondary prevention.
• The findings support the use of evolocumab for patients across the cardiovascular risk spectrum.
• Personalized therapeutic strategies based on global cardiovascular risk are crucial.